Legacy Healthcare
Legacy Healthcare is a Swiss-based biopharmaceutical company pioneering the development of prescription botanical drugs for serious medical conditions, focusing on autoimmune and inflammatory diseases. Their lead product candidate, CINAINU, is a multi-target botanical drug composed of plant extracts that has demonstrated strong safety and efficacy in a phase 2/3 clinical trial for alopecia areata, a chronic autoimmune condition affecting children and adults. CINAINU offers a novel treatment approach with sustained remission off-treatment and without immune-altering side effects, positioning Legacy Healthcare as a leader in the emerging field of New Botanical Entities (NBEs). The company leverages AI and multidisciplinary expertise to develop transformative botanical drugs addressing multiple biological targets simultaneously, aiming for global leadership in this innovative therapeutic area.
Legacy Healthcare
Legacy Healthcare is a Swiss-based biopharmaceutical company pioneering the development of prescription botanical drugs for serious medical conditions, focusing on autoimmune and inflammatory diseases. Their lead product candidate, CINAINU, is a multi-target botanical drug composed of plant extracts that has demonstrated strong safety and efficacy in a phase 2/3 clinical trial for alopecia areata, a chronic autoimmune condition affecting children and adults. CINAINU offers a novel treatment approach with sustained remission off-treatment and without immune-altering side effects, positioning Legacy Healthcare as a leader in the emerging field of New Botanical Entities (NBEs). The company leverages AI and multidisciplinary expertise to develop transformative botanical drugs addressing multiple biological targets simultaneously, aiming for global leadership in this innovative therapeutic area.